MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers and First Responders
NCT05455996 · Nautilus Sanctuary
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Change from Baseline on symptoms of Post-Traumatic Stress based on the PTSD Checklist for DSM-5 (PCL-5) at Treatment Termination
Measured over Up to 17 weeks post-enrollment (Baseline)
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
3 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| Memoru | Boulder | Colorado | United States |
| InnerMost, PBC | New York | New York | United States |
| The Pearl Institute | Waynesville | North Carolina | United States |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT05455996 on ClinicalTrials.gov →
Last updated in the registry 2026-05-05. Registry records change; this page reflects the data build of 2026-08-25.
Related
Where this trial sits
Substance
Recruiting in